Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Deloitte
McKinsey
Cipla
Julphar
AstraZeneca

Generated: July 21, 2019

DrugPatentWatch Database Preview

Patent: 9,919,057

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,919,057
Title:Compounds comprising self-immolative group
Abstract: Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
Inventor(s): Kim; Yong Zu (Daejeon, KR), Park; Tae Kyo (Daejeon, KR), Woo; Sung Ho (Daejeon, KR), Kim; Sun Young (Daejeon, KR), Cho; Jong Un (Daejeon, KR), Jung; Doo Hwan (Daejeon, KR), Yang; Jeon (Daejeon, KR), Min; Ji Young (Daejeon, KR), Lee; Hyang Sook (Daejeon, KR), Park; Yun Hee (Daejeon, KR), Ryu; Jeong Hee (Daejeon, KR), Oh; Kyu Man (Daejeon, KR), Oh; Yeong Soo (Daejeon, KR), Chae; Jeiwook (Daejeon, KR), Song; Ho Young (Daejeon, KR), Chung; Chul-Woong (Daejeon, KR)
Assignee: LegoChem Biosciences, Inc. (Daejeon, KR)
Application Number:14/865,778
Patent Claims:see list of patent claims

Details for Patent 9,919,057

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Biogen ZINBRYTA daclizumab INJECTABLE;INJECTION 761029 001 2016-05-27 ➤ Sign Up LegoChem Biosciences, Inc. (Daejeon, KR) ➤ Sign Up RX search
Glaxosmithkline Llc NUCALA mepolizumab INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER 125526 001 2015-11-04 ➤ Sign Up LegoChem Biosciences, Inc. (Daejeon, KR) ➤ Sign Up RX search
Genentech ACTEMRA tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 001 2013-10-21 ➤ Sign Up LegoChem Biosciences, Inc. (Daejeon, KR) ➤ Sign Up RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08 ➤ Sign Up LegoChem Biosciences, Inc. (Daejeon, KR) ➤ Sign Up RX search
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18 ➤ Sign Up LegoChem Biosciences, Inc. (Daejeon, KR) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
AstraZeneca
US Army
Harvard Business School
Covington
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.